相关实验视频

Updated: Jul 18, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

[¹⁷⁷Lu]Lu-PSMA-617 在患有慢性脏疾病的患者的治疗中

Lorenzo Mercolli¹, Clemens Mingels², Giulia Manzini²

¹Department of Nuclear Medicine, Bern University Hospital, University of Bern, Bern, Switzerland; lorenzo.mercolli@insel.ch.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine

|August 24, 2023

概括

基于前列腺特异性膜抗原的放射性联体疗法 (RLT) 对转移性前列腺癌患者患有脏疾病具有前景. 这项研究证明了在接受血液透析的患者中成功和安全的RLT应用.

科学领域:

核医学是一种核医学.
在瘤学瘤学.
腎臟病學 (nephrology) 是一種醫學專業.

背景情况:

转移性前列腺癌带来了治疗挑战,特别是在功能受损的患者中.
自体主导多囊性病 (ADPKD) 由于潜在的毒性,使治疗决策复杂化.
基于前列腺特异性膜抗原 (PSMA) 的放射性连接体疗法 (RLT) 是转移性前列腺癌的新兴治疗方法.

研究的目的:

评估基于PSMA的RLT在患有转移性前列腺癌和需要血液透析的ADPKD患者的剂量测量结果.
评估RLT在这个特定患者群体中的安全性和有效性.

主要方法:

一名患有转移性前列腺癌和ADPKD的患者接受了6个周期的住院[177Lu]基于Lu-PSMA的RLT.
在每个RLT周期中都进行了血液透析.
用于剂量计算,使用了Voxel剂量测量和血液采样.

主要成果:

该患者对RLT表现出显著的反应,前列腺特异性抗原水平从298降至7.1 ng/mL.
剂量测量评估显示,每个循环对有风险的器官的特定辐射剂量.
每个周期观察到的剂量范围为0.19-0.4 Gy/GBq (腺),0.14-0.28 Gy/GBq (下腺),0.03-0.11 Gy/GBq (脏) 和0.10-0.15 Gy/GBq (红色骨髓).

结论:

本案例报告表明,以[177Lu]Lu-PSMA为基础的RLT可以安全有效地给经过血液透析的慢性病患者.
基于PSMA的RLT是转移性前列腺癌的可行的治疗选择,即使存在显著的功能障碍.
需要进一步的研究,以在更大的队列中证实这些发现.

关键词:

177Lu 177Lu 177Lu 177Lu 177Lu 177Lu 177Lu 177Lu 177Lu 177Lu 177 慢性脏疾病慢性脏疾病剂量测量方法剂量测量方法功能衰竭功能衰竭是什么?前列腺特异性膜抗原前列腺特异性膜抗原放射性合物治疗疗法

更多相关视频

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

The Bioconjugation and Radiosynthesis of 89Zr-DFO-labeled Antibodies

Published on: February 12, 2015

相关概念视频

Chronic Kidney Disease III: Interprofessional Care

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...

Kidney Transplant II: Surgical Procedure

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...